Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by Vinny57on Oct 25, 2018 8:12pm
173 Views
Post# 28875127

More Blah, Blah, Blah....But it's quiet right now

More Blah, Blah, Blah....But it's quiet right now

I'm sure we all know this Aphria Clan:

Canadian cannabis company Aphria plans to list on NYSE to boost liquidity, investor interest

The Ontario-based cannabis company filed with the SEC last week but has yet to set a date for its trading debut
A visual representing an upward trajectory
The company is involved in the low-cost production of safe, clean and pure pharmaceutical-grade cannabis

Canadian cannabis company Aphria Inc (TSX:APH, OTCQB:APHQF) has filed a form 40-F with US regulators to list on the New York Stock Exchange in a move that will boost liquidity and investor interest in the stock, if history is any guide.

The Leamington, Ontario-based company filed last week to list but has not yet set a date for its trading debut. Aphria’s listing would come on the back of another Canadian marijuana company Aurora Cannabis Inc’s (NYSE:ACB; TSX:ACB) much-hyped debut Tuesday on the New York Stock Exchange which was unfortunately weighed down by a broad market pullback.

The two Canadian cannabis companies follow Cronos Group Inc(NASDAQ:CRON, TSX:Cron) and Canopy Growth Corp (TSE:WEED, NYSE:CGC) in dual listing on both the Toronto Stock Exchange and a US exchange. Tilray Inc (NASDAQ:TLRY) headquartered in Nanaimo, Canada is uncommon in not also having a Canadian listing.

Aurora Cannabis CEO Terry Booth said a dual listing gave Canadian companies access to a broader group of institutional and retail investors.

"Our NYSE listing represents another important milestone that reflects our commitment to all stakeholders as we continue advancing domestic and international growth initiatives, which includes expanding our base of global institutional and retail investors," said Booth.

READ: Aphria reports higher 1Q fiscal first quarter revenue and looks ahead to cannabis legalization in Canada

Cronos, which listed on the Nasdaq in February, saw its daily trading volume jump from an average of 1.5 million in the week before its Nasdaq listing to a combined 12.8 million the week after, according to Bloomberg data. Canopy’s volume rose from 8.5 million the week before its May listing to 10.3 million after.

Aphria reported higher fiscal first-quarter revenues last week from strong sales. The company said in a statement revenue for the period ending on August 31, 2018, reached C$13,292, 10% higher than the prior quarter's C$12,026 and 117% higher than the same period last year.

Aphria CEO Vic Neufeld said the company "continued to ramp up our production capabilities" and moved "forward aggressively with the implementation of our automation infrastructure, which is expected to streamline production over the medium to longer terms."

"We believe the automation investment in particular will provide Aphria with a significant competitive advantage and further our industry-leading low-cost structure," said Aphria.

Aphria said Canadian-based production capacity is on schedule to reach 255,000 kgs per annum.

The company has supply agreements with every province in Canada and the Yukon Territory, ensuring access to Aphria products for 99.8% of the Canadian population.

Aphria has launched the company's initial portfolio of adult-use brands: Solei Sungrown Cannabis, RIFF, Good Supply, and Goodfields.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter@UttaraProactive 

 

Bullboard Posts